AI-based early detection of pancreatic cancer using routine CT scans

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate an AI-powered system for the early detection of pancreatic cancer and its precursor lesions through non-contrast computed tomography (NCCT) scans performed during routine clinical visits. By utilizing existing imaging resources, the study seeks to enhance screening coverage among high-risk populations without the need for additional infrastructure. The AI model will automatically identify pancreatic abnormalities, and algorithm-positive cases will be reviewed by radiologists for further diagnostic verification. Patients with confirmed diagnoses will receive specialized treatment and multidisciplinary consultation.

Why it matters

Who can join: the full rules

Inclusion Criteria

1\. Individuals undergoing routine non-contrast chest and/or abdominal CT scans for non-pancreatic indications.

Exclusion Criteria

1. History of pancreatic cancer;
2. History of thoracic or abdominal surgery;
3. Acute pancreatitis within 6 months;
4. Patients referred for evaluation of suspected or confirmed pancreatic cancer.

Where it's running

• Shanghai Changhai Hospital
  Shanghai, Shanghai Municipality, China Recruiting
• Second Affiliated Hospital of Jiaxing University
  Jiaxing, Zhejiang, China Recruiting
• Yinzhou Hospital Affiliated to Medical School of Ningbo University
  Ningbo, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Wang Bei Lei, M.D.
• Email: lilly_wang@126.com
• Phone: 86-13774238083

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blood protein biomarkers to help diagnose pancreatic cancer in adults

  This study tests whether blood protein biomarkers can help detect pancreatic ductal adenocarcinoma and tell it apart from chronic pancreatitis and mucinous pancreatic lesions, and whether combining markers with CA 19-9 improves accuracy.

  Recruiting Grigore T. Popa University of Medicine and Pharmacy · Iași · NCT07875582

• AI-enhanced low-dose CT to screen for pancreatic cancer

  This project will test whether an AI tool called PANDA can read low-dose CT scans to find early pancreatic cancer in people aged 50 and older.

  Recruiting at 5 sites Changhai Hospital · Shanghai, Shanghai Municipality and 4 other locations · NCT07117045

• Registry for pancreatic cysts at UCSF

  This study is setting up a registry to track patients with pancreatic cysts to see how these cysts change over time and to help doctors make better treatment decisions.

  Recruiting University of California, San Francisco · San Francisco, California · NCT04291651

• Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery

  This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07910383

• Atebimetinib plus gemcitabine and nab‑paclitaxel as first‑line treatment for metastatic pancreatic cancer

  This trial will test whether adding the MAPK pathway drug atebimetinib to gemcitabine and nab‑paclitaxel helps people with newly diagnosed metastatic pancreatic ductal adenocarcinoma live longer.

  Recruiting at 76 sites Phase 3 Immuneering Corporation · Huntsville, Alabama and 75 other locations · NCT07562152

• Tissue adhesive (Glubran®2) to reinforce pancreaticojejunostomy in soft pancreas

  This trial will test whether adding a tissue adhesive glue (Glubran®2) to the pancreatic-jejunal connection reduces postoperative pancreatic leaks in adults with a soft pancreas undergoing pancreaticoduodenectomy.

  Recruiting Minia University · Minya, Minya Governorate · NCT07155525

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.